



PRELIMINARY PROGRAMME

Thursday, February 7th, 2019

08:00 Registration

08:45 **Opening**

A. Artigas, MD (Sabadell, Spain)
J. Carlet, MD (Paris, France)
J. Garnacho, MD (Sevilla, Spain)
M. Niederman, MD (New York, USA)
A. Torres, MD (Barcelona, Spain)

I. SEPSIS

Moderators: A. Artigas, MD (Sabadell, Spain)
H. Gerlach, MD (Amsterdam, The Netherlands)

09:00 **Year Update and Clinical Review: Sepsis and Septic Shock**

A. Perner, MD (Copenhagen, Denmark)

09:20 **Long-term Burden of Sepsis: Enhancing Recovery**

R. Ferrer, MD (Barcelona, Spain)

09:40 **Elderly Patients with Sepsis or Ageing in Sepsis**

B. Guidet, MD (Paris, France)

10:00 **We Have So many Negative Clinical Trials : A Revisited Design**

J. Russell, MD (Vancouver, Canada)

10:20 Discussion

10:30 **Coffee- Break (Exhibition Area & Poster Discussion)**

II. FLUID THERAPY AND VASSOPRESSORS

Moderators: C. Martin, MD (Marseille, France)
JL. Teboul, MD (Paris, France)

11:00 **New Vasoactive Agents**

J. Russell, MD (Vancouver, Canada)

11:20 **Miocardial Involvement in Sepsis**

M. Cecconi, MD (Milan, Italy)

11:40 **Balanced Crystalloids versus Saline in Sepsis**

J. Kellum, MD (Pittsburgh , USA)



12:00 **Fluid Responsiveness Limitations**
JL. Teboul, MD (Paris, France)

12:20 Discussion

12:30 **Debate: Corticosteroids in Septic Shock**
Moderator: P. Povoas, MD (Lisboa, Portugal)
Pro: D. Annane, MD (Paris, France)
Con: A. Perner, MD (Copenhagen, Denmark)

13:10 **Lunch**

III. KIDNEY IN SEPSIS

Moderators : M. Antonelli, MD (Rome, Spain)
J. Kellum, MD (Pittsburgh, USA)

14:10 **Pathophysiology of Septic AKI**
J. Kellum, MD (Pittsburgh, USA)

14:30 **New Biomarkers to Predict AKI**
P. Honoré, MD (Brussels, Belgium)

14:50 **Vasopressors and the Kidney**
C. Martin, MD (Marseille, France)

15:10 **CRRT in Sepsis**
M. Herrera, MD (Málaga, Spain)

15:30 **Prevention of AKI**
P. Pickkers, MD (Nijmegen, The Netherlands)

15:50 Discussion

IV. PERSONALIZE SEPSIS CARE

Moderators : R. Ferrer, MD (Barcelona, Spain)
I. Martin-Loeches, MD (Dublin, Ireland)

16:00 **Influence of Time Period Symptoms in Biomarkers in CAP**
A. Torres, MD (Barcelona, Spain)

16:20 **Phenotyping of Patients with Sepsis**
H. Gerlach, MD (Berlin, Germany)



16:40 **Immune Suppression in Sepsis**
T. Calandra, MD (Lausanne, Switzerland)

17:00 Discussion

17:10 **Coffee- Break (Exhibition Area)**

V. NEW TREATMENTS IN SEPSIS

Moderators : M. Schultz, MD (Amsterdam, The Netherlands)
D. Annane, MD (Paris, France)

17:40 **Novel Antiinflammatory Therapies**
P. Pickkers, MD (Nijmegen, The Netherlands)

18:00 **Adjunctive Therapy in Sepsis- Old friends vs new trials**
J. Russell, MD (Vancouver, Canada)

18:20 **Blood Coagulation in Sepsis and ARDS**
M. Camprubí, MD (Sabadell, Spain)

18:40 **Discussion**

Friday, February 8th, 2019

09:00 **Clinical Year Review: Pulmonary Infections**
M. Niederman, MD (New York, USA)

VI. SEVERE COMMUNITY-ACQUIRED PNEUMONIA

Moderators: A. Torres, MD (Barcelona, Spain)
J. Chastre, MD (Paris, France)

09:20 **Epidemiology and Outcome of Severe CAP**
M. Ferrer, MD (Barcelona, Spain)

09:40 **In the Immunocompromised**
E. Azoulay, MD (Paris, France)

10:00 **A Place for Immunoglobulins?**
I. Martin-Loeches, MD (Dublin, Ireland)

10:20 **How To Improve Outcomes**
M. Niederman, MD (New York, USA)

10:40 Discussion



10:50 **Coffee- Break (Exhibition Area & Poster Discussion)**

VII. THE MICROBIOME IN CRITICAL ILLNESS

Moderators : M. Niederman, MD (New York, USA)
J. Carlet, MD (Paris, France)

11:20 **Should We Check The Microbiome Preventing Infections?**
M. Schultz, MD (Amsterdam, The Netherlands)

11:40 **Ways To Prevent the Acquisition of MRB in The Gut Microbiota of ICU Patients**
J. Carlet, MD (Paris, France)

12:00 **SDD/SOD and Probiotics**
L. Bos, MD (Amsterdam, The Netherlands)

12:20 Discussion

12:30 **Debate : Aerosol Antibiotics For Pneumonia**
Moderator: J. Chastre, MD (Paris, France)
PRO: M. Niederman, MD (New York, USA)
CON: P. Povoas, MD (Lisboa, Portugal)

13:10 **Lunch**

VIII. DIAGNOSTIC TOOLS IN PULMONARY INFECTION AND SEPSIS

Moderators : H. Gerlach, MD (Amsterdam, The Netherlands)
P. Povoas, MD (Lisboa, Portugal)

14:10 **Caveats of Molecular Testing For Diagnosing Bacterial Infections**
E. Bouza, MD (Madrid, Spain)

14:30 **Beta D Glucan Driven Antifungal Therapy**
M. Antonelli, MD (Rome, Italy)

14:50 **Should We and How Could We Differentiate VAT from VAP?**
S.Nseir, MD (Lille, France)

15:10 **Cardiac Biomarkers in CAP**
R. Menéndez, MD (Valencia, Spain)

15:30 Discussion

15:40 Coffee-Break



IX. OPTIMIZING ANTIMICROBIAL THERAPY

Moderators : A. Paiva, MD (Porto, Portugal)
J. Rodriguez-Baño, MD (Seville, Spain)

16:00 Role of New Antibiotics

M. Niederman, MD (New York, USA)

16:20 When No To Start Broad-Spectrum Antibiotic in The ICU

J. Chastre, MD (Paris, France)

16:40 Prolonged Infusion of Beta-Lactams: Do We Have Enough Data?

J. De Waele, MD (Ghent , Belgium)

17:00 Bacteriophage Therapy to Combat Bacterial and Fungal Infection

P. Ramirez (Valencia, Spain)

17:20 Task Force on Practical Management of Invasive Candidiasis In Critically Ill Patients

I.Martin-Loeches, MD (Dublin, Ireland)

17:40 Combination versus Monotherapy

J. Garnacho, MD (Sevilla, Spain)

18:00 Closing Remarks